Liver Abscesses as a Sign of Chronic Granulomatous Disease in Adolescent

Hussain A. Al Ghadeer, Fadi N. Busaleh, Jaber A. Al Habeeb, Rabab M. Alaithan, Abdullah E. Almutahhar, Murtadha M. Bin Abd, Mishael M. Aldawood

1. Pediatrics, Maternity and Children Hospital, AlAhsa, SAU
2. Allergy and Immunology, Maternity and Children Hospital, AlAhsa, SAU

Corresponding author: Hussain A. Al Ghadeer, hu.alghadeer@gmail.com

Abstract

Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency disease caused by a genetic defect in the nicotinamide adenine dinucleotide phosphate oxidase (NADPH) complex that affects phagocytes. This leads to recurrent severe bacterial and fungal infections manifested by recurrent pneumonia, also involving soft tissue, bones, and liver. Usually, CGD is presented and diagnosed in the first five years of life. In this case report, we describe a late presentation in an adolescent with multiple liver abscesses, the approach of diagnosis, and management.

Categories: Genetics, Pediatrics, Allergy/Immunology
Keywords: chronic granulomatous disease, primary immunodeficiency disorder, liver abscess, x-linked genetic diseases, nadph oxidase deficiency

Introduction

Chronic granulomatous disease (CGD) is described as a rare primary immunodeficiency disease (PID) caused by a defect in one of the five subunits of the nicotinamide adenine dinucleotide phosphate oxidase (NADPH) complex, which impairs respiratory burst. Two-thirds of cases are inherited as X-linked [1]. The incidence of CGD is estimated to be one in every 200,000 to 250,000 live births [2]. The majority of cases are diagnosed early before five years of age, although the diagnosis can be made at any age. As a result of the genetic defect that impairs phagocyte function, patients with CGD are at high risk for recurrent life-threatening catalase-positive bacteria and fungal infections. The most common organisms are Staphylococcus aureus, Burkholderia onionensis, Serratia muclagle, Nocardia, and Aspergillus, which affect the skin, lymph nodes, bone, and liver [3]. This report describes a child with the later presentation of CGD through persistent fever and a liver abscess.

Case Presentation

This is a 12-year-old Saudi boy presented to Maternity and Children’s Hospital - Alhassa in Saudi Arabia with a history of intermittent fever that initially responded to antipyretics but after few days the fever became continuous without response to antipyretics and antibiotics. It was associated with intermittent cough, non-productive, and without diurnal variation. Also, it was associated with weight loss around 8 kilograms, anorexia, epigastric pain non-specific, with episodes of vomiting. There was no history of recurrent infections, bone pain, hair loss, skin rash, or family history of immunodeficiency or haematological disorders like sickle cell anaemia. There was a history of the previous admission about a year ago with lobar pneumonia and parapneumonic effusion that responded well to 10 days course of antibiotic therapy. On examination, the patient looked ill, was lethargic without pain or dyspnea, febrile 38.6°C, HR: 100 beats/min, RR: 25 breaths/min, BP: 112/62 mmHg, O₂ saturation: 98% on room air. Weight was 22 kg below the third percentile. There is decreased air entry in the right lower chest, the rest of the exam was unremarkable. Laboratory findings (Table 1) revealed leukocytosis (neutrophilia) with microcytic hypochromic anaemia and hypoalbuminemia with a normal hepatic renal profile.

How to cite this article
Al Ghadeer H A, Busaleh F N, Al Habeeb J A, et al. (August 26, 2021) Liver Abscesses as a Sign of Chronic Granulomatous Disease in Adolescent. Cureus 13(8): e17467. DOI 10.7759/cureus.17467
| Laboratory Test                        | Patient Result                                                                 |
|---------------------------------------|-------------------------------------------------------------------------------|
| Complete Blood Count                  |                                                                               |
| Haemoglobin                           | 8.5                                                                           |
| Reference Level: 11.5-13.5             |                                                                               |
| White Blood Cells                     | 14.92                                                                         |
| Reference Level: 4.5-13.5*10<sup>3</sup> |                                                                               |
| Platelets                             | 415                                                                           |
| Reference Level: 150-350*10<sup>3</sup> |                                                                               |
| Blood Chemistry Tests                 |                                                                               |
| Total Bilirubin (TBIL)                | 0.6                                                                           |
| Reference Level: 0.00 to 1.00 mg/dL   |                                                                               |
| Direct Bilirubin (DBIL)               | 0.43                                                                          |
| Reference Level: 0.00 to 0.20 mg/dL   |                                                                               |
| Albumin                               | 19                                                                            |
| Reference Level: 34 to 54 g/L         |                                                                               |
| Aspartate Aminotransferase (AST)      | 32                                                                            |
| Reference Level: 15 to 37 IU/L        |                                                                               |
| Alanine Aminotransferase (ALT)        | 22.8                                                                          |
| Reference Level: 0.00 to 35 IU/L      |                                                                               |
| Erythrocyte Sedimentation Rate (ESR)  | 101                                                                           |
| Reference Level: 0 and 20 mm/hr       |                                                                               |
| Coagulation Profile                   |                                                                               |
| Prothrombin Time (PT)                 | 14.9                                                                          |
| Reference Level: 12.7 to 16.1 seconds |                                                                               |
| Partial Thromboplastin Time (PTT)     | 43                                                                            |
| Reference Level: 33.9 to 46.1 seconds |                                                                               |
| International Normalized Ratio (INR)  | 1.16                                                                          |
| Reference Level: 0.79 to 1.30         |                                                                               |
| Imaging                               |                                                                               |
| Chest X-ray                           | Right lower lung opacity                                                     |
| Abdominal Ultrasound                  | Multiple hepatic abscess                                                     |
| CT Scan Abdomen and chest             | linear atelectasis in both lungs with left lung solitary pulmonary nodule and multifocal hepatic pyogenic abscesses |

**TABLE 1: Laboratory and imaging investigations**

Chest x-ray (Figure 1) initially showed infiltration of the right lower lobe. Abdominal Ultrasound showed multiple liver abscesses. Blood culture was obtained, and a broad-spectrum antibiotic was started covering...
gram-positive and negative organisms as well as anaerobes. A computed tomographic study (CT) of the chest and abdomen (Figures 2, 3) showed linear atelectasis in both lungs with a solitary nodule in the left lung and multifocal pyogenic liver abscesses. The liver abscess was drained by ultrasound-guided procedure and the drained pus was cultured and showed S. aureus. The patient was treated with culture-sensitive antibiotics for 10 days. Since pulmonary infection and unusual abscess site were noted, oxidative burst test and immunoglobulin level were requested to roll out immunodeficiency disorders. The result was positive for the oxidative burst test and a normal immunoglobulin level. Based on the clinical features and investigations, a diagnosis of CGD was made. The patient was discharged home with prophylactic antibiotics and antifungals and seen regularly by an immunologist.

FIGURE 1: Chest x-ray, AP view, showing opacity in the right lower lung with vascular markings, normal cardiothoracic shadow with no obliteration of the costophrenic angles.
FIGURE 2: CT scan of the chest, axial view with no contrast showing multiple linear opacities in both lungs suggestive of bilateral linear atelectasis (red arrows) and a single solitary lung nodule in left lung measures 10*11 mm (blue arrow).

FIGURE 3: CT scan of the abdomen, axial plane with no contrast showing multiple cystic lesions in the left liver lobe (subcapsular in location) grape-like suggestive of hepatic abscesses.
Discussion

The NADPH oxidase complex consists of five proteins: gp91phox, p22phox, p47phox, p67phox, p40phox, and a sixth protein EROS as a stabilizer [4]. Any defect in any of these proteins can lead to CGD. Approximately 65%-70% of cases are inherited as X-linked due to mutations in the CYBB gene, which encodes gp91phox. CGD can also be inherited in an autosomal recessive manner when the mutations occur in the NCF1, NCF2, CYBA, and NCF4 genes, which encode p47phox, p67phox, p22phox, and p40phox, respectively [5]. In the last decade, the survival rate has improved significantly, allowing more than 50% of patients with CGD to live at least until the age of 25 years, whereas 60 years ago the survival rate was less than 40% [6,7]. Although the survival rate has improved, it depends on the clinical patterns, mode of inheritance, as X-linked inheritance is more severe and the mortality rate is higher, which defect occurs at which gene, and the type and location of the mutation. All these factors may play an important role in the survival rate [8,9].

CGD is characterized by recurrent life-threatening bacterial and fungal infections that occur due to the impairment of the enzyme NADPH oxidase. The majority of cases are caused by catalase-positive organisms. The most common organisms are S. aureus, Serratia, Burkholderia, Pseudomonas as bacteria and Aspergillus and Candida as fungi [10]. In this case, the culture was positive for S. aureus. Also, as a result of prolonged inflammatory response due to defect in oxidant production by phagocytes leading to granuloma formation [11]. The pattern of presentation varies from patient to patient. Globally, recurrent pulmonary infections are the main symptoms followed by soft tissue infections "lymphadenitis", which is most common in Middle Eastern countries. Our patient had persistent fever and liver abscess, which in most cases occurred as later complications and were not the usual presenting sign. Primary Immunodeficiency disorders should be considered when there are red flags warning of immunodeficiency investigations (Table 2) [12]. CGD is considered when there is recurrent pulmonary infection or abscesses in unusual locations [13].

Although CGD is rare, it should be diagnosed if strongly suspected. Nitroblue tetrazolium test (NBT) is usually reduced to formazan. In CGD, NBT is not reduced due to a failure of superoxide formation. Dihydrorhodamine-1,2,3 assay (DHR) is a flow cytometric analysis that evaluates NADPH activity. DHR is more sensitive [14,15].

Early diagnosis of CGD is critical for effective treatment and good outcomes. Acute infection should be treated aggressively with antibiotics, followed by prophylactic antibiotic with sulfamethoxazole-trimethoprim and antifungal azoles, which significantly reduces morbidity and mortality. Curative therapy for CGD is by hematopoietic stem cell (HSC) transplantation. For those who are not human leukocyte antigen (HLA) identical, genetic modification of autologous HSCs can be used as an alternative therapy [16].

| Red flags for primary immunodeficiency disorders |
|-------------------------------------------------|
| Recurrent infection                             |
| Invasive infection                              |
| Atypical pathogens                              |
| Partial response to antibiotic treatment or prolonged course |
| Failure to thrive                               |
| Chronic diarrhea                                |
| Fungal infections, unexplained and unusual in site |
| Unexplained skin rash                           |
| Family history of immunodeficiency              |

TABLE 2: Red flags for primary immunodeficiency disorders

Conclusions

Infections are essential for the development of children's immune systems. They serve as a battleground for the formation and recruitment of children's immune systems. These infections vary with their degree, but they have a range of acceptability and the consequences when they go beyond suggest immune deficiency disorders. Recurrent lung and soft tissue abscesses are the main signs of CGD, but not the only ones. The presence of an abscess, in which S. aureus is growing, is highly suggestive of an NADPH oxidase complex defect called CGD. Usually seen in the first decade of life especially the first half but the delayed presentation is reported. The management of this is aimed at treatment of current infection, but usually, the
management of this patient is difficult, burden with complications that required surgical intervention and prophylaxis of subsequent infection. Outcomes today are favourable due to the development of hematopoietic stem cell transplantation.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Warren M, Shimada H: Cytologic and ultrastructural findings of bronchoalveolar lavage in patients with chronic granulomatous disease. Pediatr Dev Pathol. 2018, 21:547-54. 10.1177/1093526617736188
2. Mahdaviani SA, Mohajerani SA, Rezaei N, Casanova IL, Mansouri SD, Velayati AA: Pulmonary manifestations of chronic granulomatous disease. Expert Rev Clin Immunol. 2013, 9:153-60. 10.1586/eri.12.98
3. Roos D: Chronic granulomatous disease. Br Med Bull. 2016, 118:50-65. 10.1093/bmbld/mw009
4. Arnadottir GA, Norddahl GL, Gudmundsdottir S, et al.: A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease. Nat Commun. 2018, 9:4447. 10.1038/s41467-018-06964-z
5. Roos D, Kuhns DB, Maddalena A, et al.: Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis. 2010, 45:246-65. 10.1016/j.bcmd.2010.07.012
6. Rider NL, Jameson MB, Creech CB: Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. 1 Pediatric Infect Dis Soc. 2018, 7:52-5. 10.1093/jpids/pwy008
7. Fayszy F, Khashayar K, Nirouei M, Tavakol Z, Askarimohammad F, Tavakol M: Chronic granulomatous disease (CGD): epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management. Immunol Genetics J. 2020, 3:16-29. 10.22034/igj.2020.242713.1045
8. Arnold DE, Heimall JR: A review of chronic granulomatous disease. Adv Ther. 2017, 34:2545-57. 10.1007/s12325-017-0656-2
9. Anjani G, Vignesh P, Joshi V, Sandilija JK, Bhattarai D, Sharma J, Rawat A: Recent advances in chronic granulomatous disease. Genes Dis. 2020, 7:84-92. 10.1016/j.gendis.2019.07.010
10. van den Berg JM, van Koppen E, Ahlin A, et al.: Chronic granulomatous disease: the European experience. PLoS One. 2009, 4:e5254. 10.1371/journal.pone.0005254
11. Segal BH, Grimm MJ, Khan AN, Han W, Blackwell TS: Regulation of innate immunity by NADPH oxidase. Free Radic Biol Med. 2012, 53:72-80. 10.1016/j.freeradbiomed.2012.04.022
12. Toker O, Agmon-Levin N, Somech R: How to approach a patient with suspected immunodeficiency. Harefuah. 2016, 155:170-6.
13. Prince BT, Thielek BK, Williams KW, et al.: Geographic variability and pathogen-specific considerations in the diagnosis and management of chronic granulomatous disease. Pediatric Health Med Ther. 2020, 11:257. 10.2147%2FPHMT.S254253
14. Holland SM: Chronic granulomatous disease. Clin Rev Allergy Immunol. 2010, 38:5-10. 10.1007/s12016-009-8136-z
15. Kuhara DB, Alvord WG, Heller T, et al.: Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010, 363:2600-10. 10.1056/NEJMoa1007097
16. Tewari P, Martin PL, Mendizabal A, et al.: Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. Biol Blood Marrow Transplant. 2012, 18:1568-77. 10.1016/j.bbmt.2012.02.002